ODE/OIVD Fiscal 2003 Annual Report In Brief
This article was originally published in The Gray Sheet
Executive Summary
Expedited PMAs review times: Average total review time for expedited PMA applications approved by the Office of Device Evaluation and the Office of In Vitro Diagnostic Device Evaluation & Safety in FY 2003 is 374.7 days, down from 471 days in FY 2002. However, the FY 2003 figure is still nearly 16 days greater than the average time for approved original PMAs. Elapsed FDA days averaged 304 for the six expedited submissions - 58 days longer than for the total PMA approval cohort mean. In November, FDA released a guidance on the expedited review program (1"The Gray Sheet" Dec. 1, 2003, p. 9)...
You may also be interested in...
Third-Party 510(k) Reviews Increasingly Time-Consuming For CDRH – Kahan
CDRH is hosting a face-to-face training session for "accredited persons" as part of ongoing efforts to improve its third-party review program
Third-Party 510(k) Reviews Increasingly Time-Consuming For CDRH – Kahan
CDRH is hosting a face-to-face training session for "accredited persons" as part of ongoing efforts to improve its third-party review program
CDRH FY 2005 Budget Proposal Designates 12 New FTEs For Outside Expertise
FDA's device center could hire 59 additional full-time review staffers in fiscal 2005, based on proposed growth in budget authority and user fee revenue